| Model 1 (5-subgrouping) | Model 2 (4-subgrouping) | ||||||
---|---|---|---|---|---|---|---|---|
Variables | Disease-free survival | Overall survival | Disease-free survival | Overall survival | ||||
 | HR (95%CI) | P-value | HR (95%CI) | P-value | HR (95%CI) | P-value | HR (95%CI) | P-value |
Molecular subtyping | Â | Â | Â | Â | Â | Â | Â | Â |
   IHC-Luminal A |  |  |  |  | 1.00 |  | 1.00 |  |
   IHC-Luminal B |  |  |  |  | 1.48 (1.04-2.09) | 0.027 | 1.86 (1.11-3.11) | 0.018 |
   IHC-HER2 |  |  |  |  | 1.60 (1.11-2.31) | 0.011 | 3.07 (1.86-4.87) | < 0.001 |
   IHC-TNBC |  |  |  |  | 1.19 (0.89-1.68) | 0.293 | 2.91 (1.88-4.48) | < 0.001 |
Molecular subtyping | Â | Â | Â | Â | Â | Â | Â | Â |
   IHC-Luminal A | 1.00 |  | 1.00 |  |  |  |  |  |
   IHC-Luminal B | 1.48 (1.04-2.09) | 0.028 | 1.86 (1.11-3.11) | 0.018 |  |  |  |  |
   IHC-HER2 | 1.60 (1.11-2.31) | 0.012 | 3.07 (1.86-4.87) | < 0.001 |  |  |  |  |
   IHC-BLBC | 1.03 (0.68-1.56) | 0.874 | 2.80 (1.68-4.68) | < 0.001 |  |  |  |  |
   IHC-QNBC/5NP | 1.43 (0.93-2.18) | 0.102 | 3.04 (1.75-5.26) | < 0.001 |  |  |  |  |
Tumor size (cm) | Â | Â | Â | Â | Â | Â | Â | Â |
   ≤ 2 cm | 1.00 |  | 1.00 |  | 1.00 |  | 1.00 |  |
   2-5 cm | 1.39 (1.06-1.86) | 0.02 | 2.26 (1.46-3.50) | < 0.001 | 1.39 (1.05-1.85) | 0.021 | 2.26 (1.46-3.39) | < 0.001 |
   > 5cm | 2.19 (1.44-3.36) | < 0.001 | 3.21 (2.13-4.67) | < 0.001 | 2.16 (1.42-3.32) | < 0.001 | 3.19 (1.78-5.73) | < 0.001 |
LN involvement | Â | Â | Â | Â | Â | Â | Â | Â |
   Negative | 1.00 |  | 1.00 |  | 1.00 |  | 1.00 |  |
   Positive | 2.40 (1.82-3.16) | < 0.001 | 3.17 (2.14-4.61) | < 0.001 | 2.41 (1.83-3.18) | < 0.001 | 3.17 (2.14-4.61) | < 0.001 |
Adjuvant Chemotherapy | Â | Â | Â | Â | Â | Â | Â | Â |
   Not done | 1.00 |  | 1.00 |  | 1.00 |  | 1.00 |  |
   Done | 0.70 (0.50-0.99) | 0.049 | 0.34(0.22-0.50) | < 0.001 | 0.70 (0.50-0.99) | 0.048 | 0.34 (0.22-0.50) | < 0.001 |